Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.
APA
Le X, Brase JC, Bao W (2026). Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.. The New England journal of medicine, 394(6), 622. https://doi.org/10.1056/NEJMc2517517
MLA
Le X, et al.. "Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.." The New England journal of medicine, vol. 394, no. 6, 2026, pp. 622.
PMID
41885993
같은 제1저자의 인용 많은 논문 (4)
- Brief Report: Treatment Patterns and Outcomes in a Large Real-World Cohort of Patients With ES-SCLC Treated With First-Line Chemoimmunotherapy in the United States.
- Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
- Treatment options and considerations for acquired resistance in EGFR mutation-positive non-small-cell lung cancer.
- Sevabertinib in Advanced -Mutant Non-Small-Cell Lung Cancer.